ロード中...
Fibrostenotic strictures in Crohn’s disease
The use of biologic agents including anti-tumor necrosis factor monoclonal antibodies followed by anti-integrins and anti-interleukins has drastically changed the treatment paradigm of Crohn’s disease (CD) by improving clinical symptoms and mucosal healing. However, up to 70% of CD patients still ev...
保存先:
| 出版年: | Intest Res |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Korean Association for the Study of Intestinal Diseases
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7609387/ https://ncbi.nlm.nih.gov/pubmed/32259917 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2019.09148 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|